AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32875451
Drug: Pomegranate peel
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate peel supplementation via diet (1 g PP powder/kg diet)
Trial: 32875451
Drug: Pomegranate peel
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate peel supplementation via diet (2 g PP powder/kg diet)
Trial: 32875451
Drug: Hg +
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hg + Pomegranate peel supplementation via water (0.3 g L‐1)
Trial: 32875451
Drug: Hg +
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hg + Pomegranate peel supplementation via diet (1 g PP powder/kg diet)
Trial: 32875451
Drug: Hg +
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hg + Pomegranate peel supplementation via diet (2 g PP powder/kg diet)
Trial: 32029429
Drug: Cervical injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical injection of 99m Tc at the 3 and 9 o'clock positions of the uterine cervix
Trial: 32029429
Drug: Endometrial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial injection of 99m Tc into the fundal endometrium using a transcervical catheter
Trial: 36149164
Drug: Conventional field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional field EBRT 50 Gy with concurrent weekly chemotherapy followed by ICBT
Trial: 36149164
Drug: Extended field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended field EBRT 50 Gy with concurrent weekly chemotherapy followed by ICBT
Trial: 33300853
Drug: Systemic rehydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic rehydration (oral fluid consumption)
Trial: 32325164
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose water (D5W) and corticosteroid (triamcinolone acetonide, 10mg/mL) injection
Trial: 32325164
Drug: Corticosteroid (triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (triamcinolone acetonide, 10mg/mL) injection
Trial: 32007991
Drug: Global Postural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Global Postural Reeducation (GPR) method, implemented for 72 treatment sessions, 3 times a week for 24 weeks
Trial: 34243836
Drug: TYRX Absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TYRX Absorbable Antibacterial Envelope adjunctive to standard of care
Trial: 35815323
Drug: Intracervical injection
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical injection of combination liposomal bupivacaine and bupivacaine
Trial: 33539955
Drug: Gastroretentive tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastroretentive tablets containing cilnidipine
Trial: 33539955
Drug: Reference tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference tablets
Trial: 34483276
Drug: Azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20 mg/kg height-based dosing) administered 4 times per year for 1 year
Trial: 33728657
Drug: Combined Oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Oral Contraceptive Pill (COCP)
Trial: 36265101
Drug: Triple metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple metronomic chemotherapy (TMC): oral methotrexate 9 mg/m2 once a week, celecoxib 200 mg twice daily, erlotinib 150 mg once daily
Trial: 36265101
Drug: TMC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC with intravenous nivolumab (TMC-I): TMC plus nivolumab 20 mg flat dose once every 3 weeks
Trial: 34928182
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion (ILE) - 100 ml of 20% ILE bolus followed by 100 ml of 20% ILE infusion over 6 hours
Trial: 32275359
Drug: Fire needling
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire needling treatment (at Lianquan (CV 23), Fengchi (GB 20), Wangu (GB 12), Shuigou (GV 26), Neiguan (PC 6), and Zusanli (ST 36) without needle retaining every other day)
Trial: 32016519
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with simethicone plus NAC 600 mg
Trial: 34040762
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg melatonin tablets
Trial: 34040762
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg melatonin tablets
Trial: 35505174
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg intravenous rhPro‐UK (n = 40)
Trial: 35505174
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous rhPro‐UK (n = 39)
Trial: 35505174
Drug: 0.9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg recombinant tissue plasminogen activator (r‐tPA; n = 40)
Trial: 36334720
Drug: Epinephrine 1
RxNorm normalized name: epinephrine 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 1 mg intranasal spray (neffy)
Trial: 36334720
Drug: Manual intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual intramuscular epinephrine 0.3 mg injection
Trial: 36334720
Drug: Epinephrine 0.3
RxNorm normalized name: epinephrine 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.3 mg autoinjectors (Symjepi)
Trial: 36334720
Drug: Epinephrine 0.3
RxNorm normalized name: epinephrine 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.3 mg autoinjectors (EpiPen)
Trial: 32147750
Drug: SPT-07A 10
RxNorm normalized name: NV-07a
DrugBank: NV-07a (DB05845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPT-07A 10 mg
Trial: 32147750
Drug: SPT-07A 20
RxNorm normalized name: NV-07a
DrugBank: NV-07a (DB05845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPT-07A 20 mg
Trial: 32147750
Drug: SPT-07A 40
RxNorm normalized name: NV-07a
DrugBank: NV-07a (DB05845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPT-07A 40 mg
Trial: 33307959
Drug: Dopamine antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine antagonist
Trial: 33165964
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist
Trial: 35239511
Drug: Gut decontamination
RxNorm normalized name: BACILLUS CLAUSII 2000000000 ORAL SUSPENSION [SANA GUT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut decontamination (GD) with oral vancomycin-polymyxin B from day -5 through neutrophil engraftment
Trial: 32978183
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group receiving care accompanied by reinstruction and remotivation by dental assistants using the 'Oral Health Toolbox'.
Trial: 33558263
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin plus epinephrine (EI)
Trial: 33558263
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin plus sterile water (WI)
Trial: 34547165
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping with manual therapy (KTMT)
Trial: 36176051
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 30–720 mg vutiglabridin
Trial: 36176051
Drug: 240–480 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240–480 mg vutiglabridin once daily for 14 days
Trial: 36176051
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg single dose of vutiglabridin with a high-fat meal
Trial: 32678452
Drug: Inhaled vaporized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled vaporized cannabis (4.4% Δ‐9‐tetrahydrocannabinol to 4.9% cannabidiol) 3 times daily for 5 days
Trial: 32678452
Drug: Inhaled vaporized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled vaporized placebo cannabis 3 times daily for 5 days
Trial: 32678452
Drug: Inhaled vaporized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled vaporized cannabis
Trial: 32678452
Drug: Inhaled vaporized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled vaporized placebo cannabis
Trial: 35678800
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg/day orally for 12 weeks)
Trial: 35678800
Drug: Telmisartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (20 mg/day orally for 8 weeks)
Trial: 35678800
Drug: Placebo (carboxy-methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (carboxy-methyl cellulose once daily)
Trial: 32111313
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (1 mL/L Enrofloxacin 10% in drinking water for 10 days)
Trial: 32111313
Drug: Capsulated immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsulated immune yolk (12.8 g/kg)
Trial: 34658020
Drug: Intraperitoneal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal ropivacaine (150 mg in 20 mL saline)
Trial: 35301810
Drug: Rilzabrutinib 100
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib 100 mg + Ritonavir 100 mg
Trial: 35301810
Drug: Rilzabrutinib 1200
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib 1200 mg
Trial: 35301810
Drug: Rilzabrutinib 400
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib 400 mg + Ritonavir 100 mg
Trial: 34626108
Drug: Smoking Cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking Cessation Medication (SCM)
Trial: 36164138
Drug: IV Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Isatuximab (10 mg/kg)
Trial: 36164138
Drug: SC Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC Isatuximab (1000 mg)
Trial: 36164138
Drug: SC Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC Isatuximab (1400 mg)
Trial: 36164138
Drug: OBDS Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: OBDS Isatuximab (1400 mg)
Trial: 36164138
Drug: SC Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC Isatuximab (1400 mg) + OBDS
Trial: 32540634
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of standardized ashwagandha extract (Shoden®) once daily for six weeks
Trial: 34217572
Drug: Standard dose-interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose-interval (2 weeks)
Trial: 34217572
Drug: Extended dose-interval
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended dose-interval (6 months)
Trial: 34217572
Drug: Both dose-intervals
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dose-intervals
Trial: 36198461
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TT) + Long pulse width stimulation (LPWS)
Trial: 36198461
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TT) + neuromuscular electrical stimulation via telehealth
Trial: 35217515
Drug: PRN ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PRN ranibizumab monotherapy, n=119
Trial: 33449396
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water (0.2 mL)
Trial: 33449396
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (58.5 mg/mL; active control)
Trial: 33449396
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (0.9 mg/mL; passive control)
Trial: 32080074
Drug: Phellinus linteus
RxNorm normalized name: PHELLINUS LINTEUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phellinus linteus (PL) 1,000 mg
Trial: 32080074
Drug: Phellinus linteus
RxNorm normalized name: PHELLINUS LINTEUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phellinus linteus (PL) 1,500 mg
Trial: 35809255
Drug: O‐R electric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O‐R electric rechargeable toothbrush (Oral‐B iO with Oral‐B Gentle Care brush head)
Trial: 35809255
Drug: Soft manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft manual toothbrush (Oral‐B Indicator)
Trial: 35022317
Drug: High-caloric fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-caloric fatty supplement (HCFS; 405 kcal/day, 100% fat)
Trial: 35022317
Drug: Ultra-high-caloric fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-high-caloric fatty supplement (UHCFS; 810 kcal/day, 100% fat)
Trial: 35022317
Drug: Ultra-high-caloric, carbohydrate-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-high-caloric, carbohydrate-rich supplement (UHCCS; 900 kcal/day, 49% carbohydrates)
Trial: 35022317
Drug: Open control
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open control (OC) group without any supplement
Trial: 33199226
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine perfusion
Trial: 33048923
Drug: SMASH intervention
RxNorm normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMASH intervention (pharmacist-led Safety Medication dASHboard)
Trial: 35412099
Drug: Heparin-free protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-free protocol
Trial: 32507535
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 6 drops of 40% damask rose essential oil
Trial: 34410498
Drug: 10% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydrogen peroxide (White Class 10%, FGM) applied once daily for 60 min to the buccal surface for 14 days
Trial: 34410498
Drug: 10% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydrogen peroxide (White Class 10%, FGM) applied once daily for 60 min to the lingual surface for 14 days
Trial: 33084088
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor blockade (using exendin9-39) before surgery
Trial: 33084088
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor blockade after RYGB
Trial: 32091596
Drug: 3-dose bivalent
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose bivalent HPV vaccine
Trial: 32091596
Drug: 1-dose bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose bivalent HPV vaccine
Trial: 32192811
Drug: RTS,S/AS01 co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 co-administered with YF and MR vaccines
Trial: 32192811
Drug: YF and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YF and MR vaccines alone
Trial: 36431088
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (sodium picosulfate plus laxatives, enemas, increased fiber, and fluid intake)
Trial: 33046141
Drug: Glyceride formulation
RxNorm normalized name: coco-glycerides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyceride formulation of EPA + DHA (2.8 g)
Trial: 33046141
Drug: Ethyl ester
RxNorm normalized name: Amben ethyl ester
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethyl ester formulation of EPA + DHA (2.8 g)
Trial: 33359437
Drug: Duodenal mucosal
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal mucosal resurfacing (DMR) combined with glucagon-like peptide-1 receptor agonist (GLP-1RA) (liraglutide) and lifestyle counseling
Trial: 36192223
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application (app) for oral hygiene guidance and motivation
Trial: 36192223
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene (SOH) instructions
Trial: 33909330
Drug: Spironolactone (SPL)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone (SPL) 200 mg/day
Trial: 33445588
Drug: Somatosensory rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatosensory rehabilitation in addition to standard physical therapy for 8 weeks
Trial: 33445588
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy for 8 weeks
Trial: 32193981
Drug: LIVE‐LiFE intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIVE‐LiFE intervention (strength and balance training integrated into daily habits, 8 visits over 12 weeks, plus US$500 in home safety changes, vision contrast screening, and medication recommendations)
Trial: 34673998
Drug: Hyperosmolar dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperosmolar dextrose injection (12.5%)
Trial: 34257675
Drug: ω‐3FA concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3FA concentrate 2000 mg (Group A)
Trial: 34257675
Drug: ω‐3FA concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3FA concentrate 2000 mg + PCC200 mcg (Group B)
Trial: 34257675
Drug: ω‐3FA concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3FA concentrate 2000 mg + PCC400 mcg (Group C)
Trial: 33824980
Drug: Cogmed Working
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cogmed Working Memory Training at home on a tablet device (N=24)
Trial: 35164864
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment for one week
Trial: 34623318
Drug: Weekly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly text assessment (n=50)
Trial: 33098496
Drug: Indoor and
RxNorm normalized name: Indoor and Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoor and outdoor dose rates (Ḋ), age‐dependent annual effective doses (AED), organ‐specific doses, lifetime attributable cancer risk
Trial: 33094958
Drug: Empirical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical therapy (triple therapy with esomeprazole, amoxicillin, and clarithromycin for 10 days)
Trial: 33094958
Drug: Tailored therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored therapy (triple or quadruple therapy with esomeprazole, metronidazole, tetracycline, and bismuth for 10 days based on genotype markers of resistance)
Trial: 34762351
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg daily intravenously
Trial: 34762351
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard COVID-19 pharmacotherapy)
Trial: 35987977
Drug: Intravenous lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lorazepam
Trial: 34032829
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 20% hypertonic saline solution plus standard care
Trial: 35762095
Drug: OHI (electric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHI (electric toothbrush and intensive oral hygiene manoeuvre adaptation)